{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:56:00Z","timestamp":1780358160072,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Eosinophilic esophagitis is a chronic inflammatory disorder of the esophagus. This real-world study used patient and physician surveys to describe the clinical characteristics and disease burden of eosinophilic esophagitis\u2014overall and in a subgroup of patients with dysphagia despite treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data analyzed in this study were collected in 2020 from US and EU patients with eosinophilic esophagitis. Eligible patients were aged\u2009\u2265\u200912 years with a diagnosis of eosinophilic esophagitis, had an esophageal count of \u2265\u200915 eosinophils\/high-power field at diagnosis, and were currently prescribed treatment for eosinophilic esophagitis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 1001 patients were included, of whom 356 (36%) had dysphagia despite treatment. Demographics and clinical characteristics were similar in both populations. The severity of eosinophilic esophagitis was mild in more patients overall (69%) versus those with dysphagia despite treatment (48%). Patient disease history was similar in both populations, with some exceptions: common patient-reported symptoms were dysphagia (70% and 86%) and heartburn\/acid reflux (55% and 49%), and common physician-reported symptoms were dysphagia (75% and 91%) and food impaction (46% and 52%). Treatment history was similar in both populations; overall, the most common treatments were proton pump inhibitors (83%) and topical corticosteroids (51%). Patients reported slightly more days with symptoms, higher impacts on activities of daily living, and slightly higher anxiety or depression in the dysphagia-despite-treatment population versus the overall population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Eosinophilic esophagitis presents severe symptoms and comorbidities that substantially impact patients\u2019 well-being and quality of life. Greater awareness of and novel treatments for eosinophilic esophagitis are needed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-024-03334-4","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T07:02:22Z","timestamp":1722668542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Patient-reported symptoms and burden of eosinophilic esophagitis: evidence from real-world clinical practice"],"prefix":"10.1186","volume":"24","author":[{"given":"Xiao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Kwiatek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Siddall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Genofre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heide","family":"Stirnadel-Farrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Katial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"issue":"5","key":"3334_CR1","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/ajg.2013.71","volume":"108","author":"ES Dellon","year":"2013","unstructured":"Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013;108(5):679\u201392.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"3334_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/2050640616689525","volume":"5","author":"AJ Lucendo","year":"2017","unstructured":"Lucendo AJ, Molina-Infante J, Arias A, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United Eur Gastroenterol J. 2017;5(3):335\u201358.","journal-title":"United Eur Gastroenterol J"},{"issue":"10","key":"3334_CR3","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1007\/s12325-020-01463-2","volume":"37","author":"RM Pokrzywinski","year":"2020","unstructured":"Pokrzywinski RM, Harding G, Brooks A, Goodwin B, Williams J. Documenting the journey of patients with eosinophilic esophagitis and the impact of the disease on patients and their caregivers: a cross-sectional, qualitative research study. Adv Ther. 2020;37(10):4458\u201378.","journal-title":"Adv Ther"},{"issue":"5","key":"3334_CR4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/ajg.2014.316","volume":"110","author":"ET Jensen","year":"2015","unstructured":"Jensen ET, Kappelman MD, Martin CF, Dellon ES. Health-Care utilization, costs, and the burden of disease related to eosinophilic esophagitis in the United States. Am J Gastroenterol. 2015;110(5):626\u201332.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"3334_CR5","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.14309\/ajg.0000000000001777","volume":"117","author":"AJ Bredenoord","year":"2022","unstructured":"Bredenoord AJ, Patel K, Schoepfer AM, et al. Disease Burden and Unmet need in Eosinophilic Esophagitis. Am J Gastroenterol. 2022;117(8):1231\u201341.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"3334_CR6","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1053\/j.gastro.2017.06.065","volume":"154","author":"KM O\u2019Shea","year":"2018","unstructured":"O\u2019Shea KM, Aceves SS, Dellon ES, et al. Pathophysiology of Eosinophilic Esophagitis. Gastroenterology. 2018;154(2):333\u201345.","journal-title":"Gastroenterology"},{"key":"3334_CR7","unstructured":"Jorveza. (budesonide) [package insert]. Freiburg, Germany: Dr. Falk Pharma GmbH; 2022."},{"key":"3334_CR8","unstructured":"Jorveza. (budesonide) [package insert]. Blainville, Quebec, Canada: AVIR Pharma Inc.; 2022."},{"key":"3334_CR9","unstructured":"Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. Gastroenterology. 2018;155(4):1022\u20131033.e10."},{"issue":"1","key":"3334_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaci.2019.10.027","volume":"145","author":"T Greuter","year":"2020","unstructured":"Greuter T, Hirano I, Dellon ES. Emerging therapies for eosinophilic esophagitis. J Allergy Clin Immunol. 2020;145(1):38\u201345.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"3334_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/apt.14194","volume":"46","author":"AJ Lucendo","year":"2017","unstructured":"Lucendo AJ, Arias-Gonzalez L, Molina-Infante J, Arias A. Systematic review: health-related quality of life in children and adults with eosinophilic oesophagitis-instruments for measurement and determinant factors. Aliment Pharmacol Ther. 2017;46(4):401\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"3334_CR12","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1053\/j.gastro.2021.06.023","volume":"161","author":"TH Taft","year":"2021","unstructured":"Taft TH, Carlson DA, Simons M, et al. Esophageal hypervigilance and symptom-specific anxiety in patients with eosinophilic esophagitis. Gastroenterology. 2021;161(4):1133\u201344.","journal-title":"Gastroenterology"},{"key":"3334_CR13","unstructured":"FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder. 2022; https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-eosinophilic-esophagitis-chronic-immune-disorder"},{"issue":"4","key":"3334_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.cgh.2017.06.036","volume":"16","author":"V Mukkada","year":"2018","unstructured":"Mukkada V, Falk GW, Eichinger CS, King D, Todorova L, Shaheen NJ. Health-related quality of life and costs Associated with Eosinophilic Esophagitis: a systematic review. Clin Gastroenterol Hepatol. 2018;16(4):495\u2013503.e8.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"3334_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1365-2214.2011.01265.x","volume":"38","author":"JP Franciosi","year":"2012","unstructured":"Franciosi JP, Hommel KA, DeBrosse CW, et al. Quality of life in paediatric eosinophilic oesophagitis: what is important to patients? Child Care Health Dev. 2012;38(4):477\u201383.","journal-title":"Child Care Health Dev"},{"issue":"9","key":"3334_CR16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1097\/MCG.0b013e3182166a5a","volume":"45","author":"TH Taft","year":"2011","unstructured":"Taft TH, Kern E, Keefer L, Burstein D, Hirano I. Qualitative assessment of patient-reported outcomes in adults with eosinophilic esophagitis. J Clin Gastroenterol. 2011;45(9):769\u201374.","journal-title":"J Clin Gastroenterol"},{"issue":"12","key":"3334_CR17","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1185\/03007990802536900","volume":"24","author":"EM Flood","year":"2008","unstructured":"Flood EM, Beusterien KM, Amonkar MM, et al. Patient and caregiver perspective on pediatric eosinophilic esophagitis and newly developed symptom questionnaires*. Curr Med Res Opin. 2008;24(12):3369\u201381.","journal-title":"Curr Med Res Opin"},{"key":"3334_CR18","doi-asserted-by":"crossref","unstructured":"Thanawala SU, Beveridge CA, Muir AB et al. Hashing out current social media use in eosinophilic esophagitis. Dis Esophagus 2021;34(11):doab059.","DOI":"10.1093\/dote\/doab059"},{"key":"3334_CR19","doi-asserted-by":"crossref","unstructured":"Chang JW, Chen VL, Rubenstein JH, Dellon ES, Wallner LP, De Vries R. What patients with eosinophilic esophagitis may not share with their providers: a qualitative assessment of online health communities. Dis Esophagus 2022;35(6):doab073.","DOI":"10.1093\/dote\/doab073"},{"issue":"11","key":"3334_CR20","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-Specific programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"3334_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1001\/jama.1966.03110020131047","volume":"197","author":"ML Kelley Jr","year":"1966","unstructured":"Kelley ML Jr., Frazer JP. Symptomatic mid-esophageal webs. JAMA. 1966;197(2):143\u20136.","journal-title":"JAMA"},{"issue":"3","key":"3334_CR22","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/0016-5085(79)90022-2","volume":"77","author":"DW Shiflett","year":"1979","unstructured":"Shiflett DW, Gilliam JH, Wu WC, Austin WE, Ott DJ. Multiple esophageal webs. Gastroenterology. 1979;77(3):556\u20139.","journal-title":"Gastroenterology"},{"issue":"6","key":"3334_CR23","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/0016-5085(78)90710-2","volume":"74","author":"RT Landres","year":"1978","unstructured":"Landres RT, Kuster GG, Strum WB. Eosinophilic esophagitis in a patient with vigorous achalasia. Gastroenterology. 1978;74(6):1298\u2013301.","journal-title":"Gastroenterology"},{"key":"3334_CR24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2147\/JAA.S193045","volume":"12","author":"TH Taft","year":"2019","unstructured":"Taft TH, Guadagnoli L, Edlynn E. Anxiety and depression in Eosinophilic Esophagitis: a scoping review and recommendations for Future Research. J Asthma Allergy. 2019;12:389\u201399.","journal-title":"J Asthma Allergy"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03334-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03334-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03334-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T07:06:15Z","timestamp":1722668775000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03334-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,3]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3334"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03334-4","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,3]]},"assertion":[{"value":"25 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to standard operating procedures. Research was conducted as a survey in accordance with the amended Declaration of Helsinki, adhering to the ICC\/ESOMAR International Code on Market, Opinion and Social Research and Data Analytics, the international code on observational research, and HIPAA (Health Insurance Portability and Accountability Act of 1996) guidelines. The survey was submitted to a central international review board (Western Institutional Review Board) and found to be exempt from ethics requirements on 23 July 2020 (Study Number: 1-1328144-1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Yes - X.X., J.K., R.K., E.G., and H.S.-F. are or were employees of AstraZeneca at the time of this study and may own stock. J.S. is an employee of Adelphi Real World, which received funding from AstraZeneca to conduct this analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"246"}}